Molecular Pathways Involved in Prostate Carcinogenesis: Insights from Public Microarray Datasets

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Baetke, Sarah C ^a,b   Adriaens, Michiel E ^a,c   Seigneuric, Renaud ^d,e   Evelo, Chris T ^a   Eijssen, Lars M T ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITÉ DE BOURGOGNE   (France)

^e INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BIOINFORMATICS; CANCER GROWTH; CARCINOGENESIS; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; MALE; METASTASIS; MICROARRAY ANALYSIS; MOLECULAR DYNAMICS; PROSTATE CANCER; PROSTATE CARCINOGENESIS;

CELL TRANSFORMATION, NEOPLASTIC; COMPUTATIONAL BIOLOGY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84869771509     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049831     Document Type: Article

References (35)

1. Hsing AW, Chokkalingam AP, (2006) Prostate cancer epidemiology. Frontiers in Bioscience 11: 1388-413.
2. Mackinnon AC, Yan BC, Joseph LJ, Al-Ahmadie HA, (2009) Molecular Biology Underlying the Clinical Heterogeneity of Prostate Cancer: An Update. Arch Pathol Lab Med 133: 1033-40.
3. Shen MM, Abate-Shen C, (2010) Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 24: 1967-2000.
4. Fitzpatrick JM, Schulman C, Zlotta AR, Schröder FH, (2008) Prostate cancer: a serious disease suitable for prevention. BJU International 103: 864-70.
5. Nelson WG, De Marzo AM, Isaacs WB, (2003) Mechanisms of disease: Prostate Cancer. N Engl J Med 349: 366-81.
6. Ross RK, Pike MC, Coetzee GA, Reichardt JK, Yu MC, et al. (1998) Androgen Metabolism and Prostate Cancer: Establishing a Model of Genetic Susceptibility. Cancer Research 58: 4497-504.
7. Flavin R, Zadra G, Loda M, (2011) Metabolic alterations and targeted therapies in prostate cancer. J Pathol 223: 283-94.
8. McDermed J (2005) Using PSA Intelligently to Manage Prostate Cancer: Part 2 of 2. PCRI Insights 8(3). Available: http://www.prostate-cancer.org/pcricms/node/121 via the Internet. Accessed 15 April 2011.
9. Venables WN, Smith DM and the R Development Core Team (2011) An Introduction to R- Notes on R: A Programming Environment for Data Analysis and Graphics. Version 2.13.0 (2011-04-13). Available: http://www.r-project.org/via the Internet.
10. Parkinson H, Sarkans U, Kolesnikov N, Abeygunawardena N, Burdett T, et al., (2011) ArrayExpress update-an archive of microarray and high-throughput sequencing-based functional genomics experiments. Nucleic Acids Res 39, D1002-4.
11. Van Iersel MP, Kelder T, Pico AR, Hanspers K, Coort S, et al. (2008) Presenting and exploring biological pathways with PathVisio. BMC Bioinformatics 9: 399.
12. Kelder T, van Iersel MP, Hanspers K, Kutmon M, Conklin BR, et al., (2012) WikiPathways: building research communities on biological pathways. Nucleic Acids Res 40, D1301-7.
13. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, et al. (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8(5): 393-406.
14. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, et al. (2008) Tumor Immunobiological Differences in Prostate Cancer between African-American and European-American Men. Cancer Res 68(3): 927-36.
15. Sun Y, Goodison S, (2009) Optimizing molecular signatures for predicting prostate cancer recurrence. Prostate 69(10): 1119-27.
16. Best CJ, Gillespie JW, Yi Y, Chandramouli GV, Perlmutter MA, et al. (2005) Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 11(19): 6823-34.
17. Gregg JL, Brown KE, Mintz EM, Piontkivska H, Fraizer GC (2010) Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection. BMC Cancer 10: 165. Available: http://www.biomedcentral.com/1471-2407/10/165 via the Internet.
18. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biology 5(10): 1-16.
19. Wu ZJ, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F (2004) A model-based background adjustment for oligonucleotide expression arrays. Journal of the American Statistical Association 99, 909-917.
20. Dai M, Wang P, Boyd AD, Kostov G, Athey B, et al., (2005) Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 33, e175.
21. Smyth G (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology 3(1): Article 3.
22. Hager MH, Solomon KR, Freeman MR, (2006) The role of cholesterol in prostate cancer. Curr Opin Clin Nutr Metab Care 9(4): 379-85.
23. Freeman MR, Solomon KR, (2004) Cholesterol and prostate cancer. J Cell Biochem 91: 54-69.
24. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR, (2005) Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 115(4): 959-68.
25. Baron A, Migita T, Tang D, Loda M, (2004) Fatty acid synthase: a metabolic oncogene in prostate cancer? J Cell Biochem 91: 47-53.
26. Lawrence MG, Veveris-Lowe TL, Whitbread AK, Nicol DL, Clements JA, (2007) Epithelial-Mesenchymal Transition in Prostate Cancer and the Potential Role of Kallikrein Serine Proteases. Cells Tissues Organs 185: 111-5.
27. Zhu ML, Kyprianou N, (2010) Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. The FASEB Journal 24(3): 769-77.
28. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4): 704-15.
29. Thiery JP, (2003) Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15: 740-6.
30. Vernon AE, LaBonne C, (2004) Tumor Metastasis: A New Twist on Epithelial-Mesenchymal Transitions. Current Biology 14: R719-21.
31. Sethi S, Macoska J, Chen W, Sarkar FH, (2011) Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am J Transl Res 3(1): 90-9.
32. Setlur SR, Royce TE, Sboner A, Mosquera JM, Demichelis F, et al. (2007) Integrative Microarray Analysis of Pathways Dysregulated in Metastatic Prostate Cancer. Cancer Res 67(21): 10296-10303.
33. Dakubo GD, Parr RL, Costello LC, Franklin RB, Thayer RE, (2006) Altered metabolism and mitochondrial genome in prostate cancer. J Clin Pathol 59: 10-16.
34. Carew JS, Huang P, (2002) Mitochondrial defects in cancer. Mol Cancer 1: 1-9.
35. Petros JA, Baumann AK, Ruiz-Pesini E, Amin MB, Sun CQ, (2005) mtDNA mutations increase tumorigenicity in prostate cancer. PNAS 102(3): 719-24.